ZTZhimin Tian

Zhimin Tian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhimin Tian has a total of 101 co-authors. Here are the top co-authors by number of shared publications:

  • Yongquan Qu

    Northwestern Polytechnical University

    17 shared publications
  • Zhixiong Guo

    School of Chemistry and Chemical Engineering Key Laboratory of Special Functional and Smart Polymer Materials of Ministry of Industry and Information Technology Northwestern Polytechnical University 710054 Xi'an China

    9 shared publications
  • Da Chen

    Key Laboratory of Special Functional and Smart Polymer Materials of Ministry of Industry and Information Technology, School of Chemistry and Chemical Engineering, Northwestern Polytechnical University, Xi'an, 710054, China

    7 shared publications
  • Shoujie Zhao

    Air Force Medical University Department of General Surgery, Tangdu Hospital Xi’an, Shaanxi 710038 , China

    6 shared publications
  • Jun Zhu

    Air Force Medical University State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Xijing Hospital of Digestive Diseases Xi’an, Shaanxi 710032 , China

    4 shared publications
  • Jun-Long Zhao

    State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Medical Genetics and Developmental Biology, Fourth Military Medical University, Xi’an, China

    4 shared publications

Latest Publications

  • Open Access

    Bioinspired IDO1-loaded Cu/ZIF for alopecia areata therapy via remodeling immune privilege

    by Yongquan Qu, Mingzhu Jin, Jiahao Ma, Zhenhua Liu, Yaoyao Li, Yuqi Wang, Xiaolei Su, Haoran Song, Bingquan Zong, Yajie Lv, et al.

    Alopecia areata (AA) is an autoimmune disease driven by the collapse of hair follicle immune privilege. Currently available treatments showed limited efficacy and high recurrence rates. Indoleamine 2,3-dioxygenase 1 (IDO1) has been recognized as critical enzyme by catalyzing tryptophan-to-kynurenine conversion to induce immunosuppression and maintain immune privilege. Aberrant IDO1 inactivation disrupts hair follicle immune privilege, causing inflammatory follicular damage and subsequent hair loss. Herein, we designed an IDO1-loaded Cu-doped zeolitic imidazolate framework (IDO@Cu/ZIF) to restore tryptophan-to-kynurenine metabolism, thereby rebuilding hair follicle immune privilege for long-term AA management. By mimicking the Cu/Zn centers in natural antioxidant enzymes, Cu/ZIF nanozymes deliver high capability to eliminate excessive reactive oxygen species in AA lesions. Meanwhile, Cu atom-induced upshift of the d-band center enhances substrate adsorption, thereby improving antioxidant performance. In vitro and in vivo experiments confirmed that IDO@Cu/ZIF reconstructs hair follicle immune privilege by restoring the tryptophan/kynurenine axis, thereby promoting hair follicle regeneration and achieving approximately 75% hair coverage. More importantly, IDO@Cu/ZIF treatment maintains long-term immune privilege and effectively suppresses AA recurrence. This study offers mechanistic insights into the rational design of high-performance antioxidant nanozymes and expands their potential applications in autoimmune diseases of AA.

  • Revascularization-driven nanozyme Therapy: Disrupting the vicious cycle of ROS and insufficient vascularization for chronic non-healing wound treatment

    by Qiuxue Jiang, Meixia Zhang, Yuqi Yang, Mingzhu Jin, Junlong Zhao, Da Chen, Boqi Jiang, Mengfan Li, Jiahao Ma, Jie Li, et al.


  • Open Access

    Nanozymes for ATP/cAMP balance restoration and ROS scavenging in inflammatory dermatosis treatment and recurrence prevention

    by Xiaolei Su, Jiahao Ma, Zhenhua Liu, Yaoyao Li, Bingquan Zong, Mingzhu Jin, Ling Liu, Jing Huang, Yajie Lv, Tianyu Cao, et al.

    Inflammatory dermatoses like psoriasis and atopic dermatitis are prevalent autoimmune disorders whose management is challenged not only by inflammatory les


  • PN-CeO2 as a potential therapeutic agent for atopic dermatitis: Antioxidant and anti-inflammatory effects

    by Ruimin Bai, Ning Wang, Baochen Cheng, Dan Han, Wenqian Du, Qiong Tian, Tingyi Yin, Ruiting Luo, Ke He, Meng Liu, et al.


  • Open Access

    Ce-UiO-66 nanozymes with charge-regulated uricase-like activity for enzyme/reagent-free detection of uric acid

    by Zhixiong Guo, Da Chen, Wei Gao, Yongquan Qu, Zhimin Tian

    Designing highly performed uricase-like nanozymes through enzymatic-like colorimetric analysis system is of vital significance for the quantitative detection of uric acid (UA). Herein, series of Ce-UiO-66 nanozymes with different surface charges through the ligand engineering strategy were rationally designed and synthesized as efficient uricase mimics with tailorable uricase-like activities to catalytically convert UA into allantoin and H2O2. Importantly, by tuning the functional groups (X = H, NO2, Br, CH3, OH) of 1,4-benzoic acid ligands, we explored the relationships between the surface charges of Ce-UiO-66-X nanozymes and their uricase-like activity. Among them, Ce-UiO-66-CH3 with the moderate surface charge exhibited optimal substrate adsorption and product desorption, displaying the highest uricase-like activity. Significantly, H2O2, as the product of UA oxidation, enabled Ce-UiO-66-CH3 itself as a dose-dependent chromogenic substrate of H2O2, giving a white-to-orange color evolution due to the Ce-UiO-66-CH3-to-CeO2 phase transition. Afterwards, a smartphone-assisted all-in-one enzyme/reagent-free biosensor based on Ce-UiO-66-CH3 was established for the precise visual detection of UA analysis, which was featured by a wide detection range (31~4000 µM), a high sensitivity (limit of detection: 8.9 µM), a rapid response (~3 min), a high structural stability and a high anti-interference ability.


  • Open Access

    Phytic acid-based nanomedicine against mTOR represses lipogenesis and immune response for metabolic dysfunction-associated steatohepatitis therapy

    by Fenghua Xu, Shoujie Zhao, Yejing Zhu, Jun Zhu, Lingyang Kong, Huichen Li, Shouzheng Ma, Bo Wang, Yongquan Qu, Zhimin Tian, et al.

    Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common chronic liver diseases and is mainly caused by metabolic disorders and systemic inflammatory responses. Recent studies have indicated that the activation of the mammalian (or mechanistic) target of rapamycin (mTOR) signaling participates in MASH progression by facilitating lipogenesis and regulating the immune microenvironment. Although several molecular medicines have been demonstrated to inhibit the phosphorylation or activation of mTOR, their poor specificity and side effects limit their clinical application in MASH treatment. Phytic acid (PA), as an endogenous and natural antioxidant in the liver, presents significant anti-inflammatory and lipid metabolism-inhibiting functions to alleviate MASH. In this study, considering the unique phosphate-rich structure of PA, we developed a cerium-PA (CePA) nanocomplex by combining PA with cerium ions possessing phosphodiesterase activity. CePA intervened in the S2448 phosphorylation of mTOR through the occupation effect of phosphate groups, thereby inhibiting the inflammatory response and mTOR-sterol regulatory element-binding protein 1 (SREBP1) regulation axis. The in vivo experiments suggested that CePA alleviated MASH progression and fat accumulation in high-fat diet-fed mice. Mechanistic studies validated that CePA exerts a liver-targeted mTOR repressive function, making it a promising candidate for MASH and other mTOR-related disease treatments.


  • Sorafenib sensitization in tumor therapy by iron overload and AMPK activation

    by Jun Zhu, Shoujie Zhao, Yejing Zhu, Shouzheng Ma, Tenghui Han, Fenghua Xu, Huichen Li, Bo Wang, Zhixiong Guo, Da Chen, et al.

    Sorafenib, as a first-line drug for advanced hepatocellular carcinoma (HCC), could trigger ferroptosis by inhibiting cystine/glutamate transporter. However, low-level intracellular iron and insufficient activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK) confer impaired response to sorafenib. In this study, a unique sorafenib nanocomposite dexterously modified with Fe-Material of Institut Lavoisier (sora@Fe-MIL) was synthesized to escalate intracellular iron level and activate AMPK, further potentiating the ferroptotic effect of sorafenib. Remarkably, this strategic deployment of sora@Fe-MIL triggered an extensive demise of cancer cells, while manifesting negligible deleterious impact on normal cells. Two prominent ferroptosis biomarkers, glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11), underwent pronounced downregulation, underscoring the efficacy of this strategy in inducing ferroptosis. Furthermore, the bioactivity of AMPK was considerably elevated, and its downstream targets were conspicuously inhibited by the treatment with sora@Fe-MIL. Using orthotopic HCC animal models, we observed a substantial suppression of primary in situ tumor growth, and ribonucleic acid (RNA) sequencing elucidated an elevated degree of ferroptosis and AMPK activation with the treatment of sora@Fe-MIL. In conclusion, we proposed that the meticulously designed strategy for secure and efficacious iron release and AMPK activation could significantly potentiate the ferroptotic impact of sorafenib, thus resuscitating its therapeutic response in HCC patients.


  • Correction to “Photoinduced Phase Transition of Ce-UiO-66 into Ce-BDC-OH”

    by Zhixiong Guo, Qian-Cheng Luo, Lei Qin, Zhimin Tian, Yan-Zhen Zheng, Yuanyuan Ma, Yongquan Qu

  • Cold to Hot: Tumor Immunotherapy by Promoting Vascular Normalization Based on PDGFB Nanocomposites

    by Shouzheng Ma, Zhimin Tian, Lei Liu, Jun Zhu, Jing Wang, Shoujie Zhao, Yejing Zhu, Jianfei Zhu, Wenchen Wang, Runmin Jiang, et al.

    Immunotherapy is a promising cancer therapeutic strategy. However, the “cold” tumor immune microenvironment (TIME), characterized by insufficient immune cell infiltration and immunosuppressive status, limits the efficacy of immunotherapy. Tumor vascular abnormalities due to defective pericyte coverage are gradually recognized as a profound determinant in “cold” TIME establishment by hindering immune cell trafficking. Recently, several vascular normalization strategies by improving pericyte coverage have been reported, whereas have unsatisfactory efficacy and high rates of resistance. Herein, a combinatorial strategy to induce tumor vasculature‐targeted pericyte recruitment and zinc ion‐mediated immune activation with a platelet‐derived growth factor B (PDGFB)‐loaded, cyclo (Arg‐Gly‐Asp‐D‐Phe‐Lys)‐modified zeolitic imidazolate framework 8 (PDGFB@ZIF8‐RGD) nanoplatform is proposed. PDGFB@ZIF8‐RGD effectively induced tumor vascular normalization, which facilitated trafficking and infiltration of immune effector cells, including natural killer (NK) cells, M1‐like macrophages and CD8+ T cells, into tumor microenvironment. Simultaneously, vascular normalization promoted the accumulation of zinc ions inside tumors to trigger effector cell immune activation and effector molecule production. The synergy between these two effects endowed PDGFB@ZIF8‐RGD with superior capabilities in reprogramming the “cold” TIME to a “hot” TIME, thereby initiating robust antitumor immunity and suppressing tumor growth. This combinatorial strategy for improving immune effector cell infiltration and activation is a promising paradigm for solid tumor immunotherapy.